Open Access Open Access  Restricted Access Access granted  Restricted Access Subscription or Fee Access

No 15 (2017)

Articles

Glubokouvazhaemye kollegi!

Fomin V.V.
Pharmateca. 2017;(15):3-3
pages 3-3 views

NEWS OF MEDICINE

- -.
Pharmateca. 2017;(15):4-6
pages 4-6 views

PATHOPHYSIOLOGICAL BASES OF REHABILITATION IN CERVICAL DYSTONY

Zalyalova Z.A., Khafizova I.F., Khayatova Z.G.

Abstract

Cervical dystonia (CD) is a local form of muscular dystonia; its pathogenesis involves central and peripheral sensorimotor mechanisms, leading to abnormal posture, imbalance, ambulation disorders, and pain. Combination of botulinotherapy and rehabilitation methods is the most effective strategy for the treatment of CD. The main methods of rehabilitation include biological feedback, multimodal kinesiotherapy programs, relaxation, vibration, and transcutaneous electrical nerve stimulation, other methods physiotherapy, active exercises for increasing muscle strength and posture correction, methods of muscle stretching, mobilization and vestibular stimulation. Each of these methods has its own pathophysiological justification for use in CD. The review presents a modern view of approaches to the therapy of CD.
Pharmateca. 2017;(15):7-15
pages 7-15 views

ACETYLSALICYLIC ACID AND PRIMARY PREVENTION: NEW OPPORTUNITIES

Laguta P.S.

Abstract

The activation of platelets and subsequent thrombus formation play a key role in the development and progression of atherosclerosis and its complications. Acetylsalicylic acid (ASA), whose clinical efficacy and safety are confirmed by numerous controlled studies and meta-analyzes, continue to be considered as a standard for antithrombotic therapy even to date. At the same time, despite the widespread and long-term experience in the use of ASA, some controversial questions regarding its application remain. The effectiveness of use ASA in high-risk patients for reducing the incidence of myocardial infarction, stroke and vascular death is beyond doubt. At the same time, the advisability of using it in low/medium-risk patients for primary prevention of cardiovascular events is not so obvious and requires a careful assessment of the expected benefit and possible risk of such therapy.
Pharmateca. 2017;(15):16-23
pages 16-23 views

Possibilities of amlodipine/lisinopril fixed-dose combination in real clinical practice

Ostroumova O.D., Kochetkov A.I., Vikentyev V.V., Pavleyeva E.E.

Abstract

The article describes an example of the use of a amlodipine/lisinopril fixed-dose combination in real clinical practice. Its high antihypertensive efficacy, favorable effect on the daily blood pressure profile, as well as the pronounced organoprotective properties, in particular, the ability to reduce the degree of left ventriclar myocardial hypertrophy and improve the resilient-elastic properties of the left heart are demonstrated.
Pharmateca. 2017;(15):24-30
pages 24-30 views

Cardiovascular safety and efficacy of celecoxib: focus on treatment and cardiosomatic rehabilitation

Lyamina N.P., Karpova E.S.

Abstract

At present time, due to demographic aging of the population, the number of comorbid diseases significantly increases. The most frequent comorbid age-related diseases is the pathology of the cardiovascular and the locomotor systems. The problem of cardiovascular safety of specific cyclooxygenase-2 inhibitors for cardiosomatic patients is one of the most acute. Previously, the use of non-steroidal anti-inflammatory drugs in patients with coronary artery disease was associated with an increased risk of cardiovascular complications, which limited their use in medical rehabilitation practice in this category of patients. The results of the PRECISION study demonstrate the cardiac safety of selective cyclooxygenase-2 inhibitors, namely celecoxib, which can contribute to the success of treatment of comorbid diseases.
Pharmateca. 2017;(15):31-36
pages 31-36 views

The use of statines in patients with arterial hypertension and chronic heart failure with preserved left ventricular ejection fraction

Kanorsky S.G., Sereda A.F.

Abstract

The prospective randomized trial included 167 patients with chronic heart failure (CHF) of II-III functional classes with preserved left ventricular ejection fraction (LVEF) against the background of III stage arterial hypertension. In addition to antihypertensive therapy with perindopril and verapamil SR (n=85) or amlodipine (n=82), atorvastatin was prescribed, which was regularly taken by 50.6 and 48.8% of patients, respectively. After 12 months, in each treatment group, the clinical status and quality of life improved, and the distance covered in the 6-minute walk test increased. Patients receiving atorvastatin had significantly reduced N-terminal pro-brain natriuretic peptide levels; there was a tendency to improvement of diastolic LV function. Addition of atorvastatin to the treatment of CHF with preserved LVEF is advisable in connection with the potential opportunity to improve the prognosis of patients.
Pharmateca. 2017;(15):37-42
pages 37-42 views

Comparative analysis of development and course of myocardial infarction in smokers and non-smokers

Korneyeva N.V., Zharskiy S.L., Shevtsov B.P., Scherban A.O., Fisenko N.K.

Abstract

The article presents the results of a retrospective analysis of 681 patients’ medical histories during 2015 with the final diagnosis of myocardial infarction, which was conducted to identify the features of myocardial infarction (MI) in smoking patients compared with non-smokers. It is shown that smoking contributes to the development of MI at a younger age, despite a less burdensome anamnesis on the concomitant cardiovascular risk factors. The course of MI in smokers is characterized by a greater size of necrosis and requires more coronary revascularization measures, including thrombolytic therapy and stenting.
Pharmateca. 2017;(15):43-48
pages 43-48 views

Trends in the use of anti-anginal preparations in the specialized outpatient clinic for the five-year period

Fitilev S.B., Shkrebneva I.I., Vozzhaev A.V., Tsukanova K.O., Dimitrova D.A.

Abstract

The article presents the results of a retrospective pharmacoepidemiological study devoted to the analysis of changes in the prescribed antianginal therapy for patients with stable angina in a specialized cardiac outpatient clinic over a five-year period. This study revealed a number of positive changes in the field of medical prophylaxis of anginal attacks at the outpatient level, to some extent consistent with national and international standards. The frequency of recommendations of cardioselective β-adrenoblockers in optimal doses increased. As to group of dihydropyridine calcium antagonists, specialists began to recommend amlodipine more often, also in higher doses. A decrease in the frequency of administration of organic nitrates and trimetazidine has been noted.
Pharmateca. 2017;(15):49-54
pages 49-54 views

Safety and efficacy of long-term therapy with high doses of atorvastatin

Ezhov M.V., Sorokin E.V.

Abstract

Cardiovascular diseases of atherosclerotic origin make a significant contribution to morbidity and mortality in Russian Federation. Hypercholesterolemia is the leading risk factor for the development of coronary artery disease (CAD). The case of early CAD due to heterozygous familial hypercholesterolemia and successful achievement of the target level of low-density lipoprotein cholesterol with the use of the maximum dose of atorvastatin and the subsequent stabilization of the course of CAD are analyzed. The original atorvastatin (Liprimar), due to the unique evidence base of randomized clinical trials conducted in patients with a very high cardiovascular risk, a reference drug with the possibility of prolonged and safe use at the maximum dosage.
Pharmateca. 2017;(15):55-60
pages 55-60 views

Cerebroprotective effects of fixed-dose combination of perindopril arginine/ indapamide

Ostroumova O.D., Ostroumova T.M., Borisova E.V., Perepelov V.A.

Abstract

The article presents a clinical case illustrating the improvement of cognitive functions, an increase in cerebral blood flow, a decrease in the left ventricular myocardial mass index against the background of treatment of a patient with a previously untreated uncomplicated hypertension with a fixed combination of an angiotensin-converting enzyme inhibitor perindopril arginine and a diuretic indapamide. The possibilities of antihypertensive therapy, in particular, the combination of perindopril with indapamide in the correction of cognitive impairments in arterial hypertension and their pathogenetic mechanisms are discussed.
Pharmateca. 2017;(15):61-67
pages 61-67 views

Energy metabolism corrector Mildronate®: interrelation of mechanisms of action and therapeutic effects

Dzerve V.Y.

Abstract

The article clarifies the mechanisms of action of meldonium (Mildronate®). It is emphasized that the evaluation of these mechanisms can significantly expand the range of application of the drug. In particular, article states that metabolic cytoprotection caused by Mildronate® is one of the promising directions in the treatment of chronic ischemia of the lower extremities, and the improvement of endothelial function against the background of use of this drug is an important pathogenetic link in improving the functional capacity of such patients. The prospects of use of Mildronate® in diabetes mellitus and such severe complications of this disease as diabetic neuropathy and nephropathy are discussed.
Pharmateca. 2017;(15):68-73
pages 68-73 views

VNIMANIYu AVTOROV!

- -.
Pharmateca. 2017;(15):73-73
pages 73-73 views

Suppression of progression of renal dysfunction and cerebrovascular events: potentials of atorvastatin

Murkamilov I.T., Aitbayev K.A., Fomin V.V., Rayimzhanov Z.R., Redzhapova N.A., Yusupov F.A., Aydarov Z.A.

Abstract

The article discusses the pathogenetic mechanisms of the development of renal dysfunction in hyperlipidemia. The data on the study of the role of statins, in particular atorvastatin, in the progression of nephrocerebral interrelations are presented. The results of a number of studies demonstrating the nephro- and cerebroprotective properties of atorvastatin have been analyzed.
Pharmateca. 2017;(15):74-82
pages 74-82 views

Importance of increasing awareness of children and adolescents about risk factors and the main symptoms of the stroke

Makarova V.D., Egiyan M.R., Orlov E.A., I S.C., Dadaeva V.A., Os'kova A.Y., Akarachkova E.S., Orlova A.S., Silina E.V.

Abstract

Untimely hospitalization of patients due to ignorance of the main stroke symptoms leads to high mortality and inefficiency of treatment. Primary prophylaxis is an effective method of preventing and reducing the consequences of this disease, because it is aimed at identifying and reducing the severity of modifiable risk factors (RFs). For successful prevention, it is necessary to take into account not only medical, but also social aspects, including related to raising awareness of the population about RFs and stroke symptoms. School awareness programs in this area are a new way of delivering the necessary information not only to the children, but also to their parents. The review includes the experience of both foreign and domestic studies in conducting similar educational programs for children. The lecture or conversation conducted by a neurologist or a teacher is the common method of providing the children with necessary knowledge in the prevention of stroke and other acute cardiovascular events. The role playing is also possible. As additional materials, brochures, leaflets, magnets, comic books, animated cartoons, and video games can be used. The main methods for assessing of acquisition of knowledge of stroke symptoms and RFs include tests that respondents complete before participating in the program and after training at different time intervals, depending on the purpose of the assessment. Educational programs aimed at increasing the awareness of schoolchildren about stroke symptoms and RFs, meet the objectives and have repeatedly confirmed effectiveness in various studies.
Pharmateca. 2017;(15):83-87
pages 83-87 views

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies